Brief: Gland Pharma Says U.S. FDA Conducted Good Manufacturing Practice Inspection At Dundigal Facility
14/07/2023 07:19
July 14 (Reuters) - Gland Pharma Ltd GLAD.NS :
* GLAND PHARMA LTD - U.S. FDA CONDUCTED GOOD MANUFACTURING
PRACTICE INSPECTION AT CO'S DUNDIGAL FACILITY AT HYDERABAD
* GLAND PHARMA LTD - INSPECTION WAS CONCLUDED WITH ONE (1)
483
OBSERVATION
Source text for Eikon: ID:nBSE30bm8h
Further company coverage: GLAD.NS
((Reutersbriefs@thomsonreuters.com;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant